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A B S T R A C T
Background
Uncontrolled bleeding is an important cause of death in trauma victims. Antifibrinolytic treatment has been shown to reduce blood
loss following surgery and may also be effective in reducing blood loss following trauma.
Objectives
To quantify the effects of antifibrinolytic drugs on mortality, vascular occlusive events, surgical intervention and receipt of blood
transfusion after acute traumatic injury.
Search methods
We searched the PubMed, Science Citation Index, National Research Register, Zetoc, SIGLE, Global Health, LILACS, and Current
Controlled Trials to March 2004 and the Cochrane Injuries Group Specialised Register, CENTRAL, MEDLINE and EMBASE to
July 2010.
Selection criteria
We included all randomised controlled trials of antifibrinolytic agents (aprotinin, tranexamic acid [TXA] and epsilon-aminocaproic
acid) following acute traumatic injury.
Data collection and analysis
The titles and abstracts identified in the electronic searches were screened by two independent authors to identify studies that had the
potential to meet the inclusion criteria. The full reports of all such studies were obtained. From the results of the screened electronic
searches, bibliographic searches, and contacts with experts, two authors independently selected trials meeting the inclusion criteria.
Main results
Four trials met the inclusion criteria, including 20,548 randomised patients. Two trials with a combined total of 20,451 patients
assessed the effects of TXA on mortality; TXA reduced the risk of death by 10% (RR=0.90, 95% CI 0.85 to 0.97; P=0.0035). Data
from one trial involving 20,211 patients found that TXA reduced the risk of death due to bleeding by 15% (RR=0.85, 95% CI 0.76 to
0.96; P=0.0077). There was evidence that early treatment (≤3 hours) was more effective than late treatment (>3 hours). There was no
evidence that TXA increased the risk of vascular occlusive events or need for surgical intervention. There was no substantial difference
in the receipt of blood transfusion between the TXA and placebo groups. The two trials of aprotinin provided no reliable data.
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Authors’ conclusions
Tranexamic acid safely reduces mortality in bleeding trauma patients without increasing the risk of adverse events. TXA should be
given as early as possible and within three hours of injury, as treatment later than this is unlikely to be effective. Further trials are needed
to determine the effects of TXA in patients with isolated traumatic brain injury.
P L A I N L A N G U A G E S U M M A R Y
Blood-clot promoting drugs for acute traumatic injury
Injury is the second leading cause of death for people aged five to 45 years. Over three million people worldwide die of injuries every
year, often because of extensive blood loss. Antifibrinolytic drugs promote blood clotting by preventing blood clots from breaking down.
Some examples of antifibrinolytic drugs are aprotinin, tranexamic acid (TXA) and epsilon-aminocaproic acid. Doctors sometimes give
these drugs to patients having surgery to prevent blood loss. They appear to have few complications. These drugs might also stop blood
loss in seriously injured patients and, as a result, save lives.
The authors of this review searched for randomised trials assessing the effects of antifibrinolytics in trauma patients. When the review
was first done in 2004 the results of the research were inconclusive. Since then, two new trials of TXA, one involving over 20,000
patients, have been completed. The results of this new research show that when given early, TXA reduces the risk of death compared
to patients who do not receive TXA without increasing the risk of side events. The review now includes data from 20,548 people who
took part in four trials.
Two small trials of aprotinin were also found although they provided no reliable data.
The authors conclude that TXA can safely reduce death in bleeding trauma patients. They suggest that future trials should explore the
effects of TXA in patients with traumatic brain injury with no other trauma.
B A C K G R O U N D
Description of the condition
For people aged five to 45 years, trauma is second only to HIV/
AIDS as a cause of death. Each year, worldwide, about three mil-
lion people die as a result of trauma (Murray 1996), many after
reaching hospital. Among trauma patients who do survive to reach
hospital, exsanguination is a common cause of death, accounting
for nearly half of in-hospital trauma deaths in some settings (Sauaia
1995). Central nervous system injury and multi-organ failure ac-
count for most of the remainder, both of which can be exacerbated
by severe bleeding (BTF 2000).
Clotting helps to maintain the integrity of the circulatory sys-
tem after vascular injury, whether traumatic or surgical in origin
(Lawson 2004). Major surgery and trauma trigger similar haemo-
static responses and the consequent massive blood loss presents an
extreme challenge to the coagulation system. Part of the response
to surgery and trauma in any patient, is stimulation of clot break-
down (fibrinolysis) which may become pathological (hyper-fibri-
nolysis) in some cases. Antifibrinolytic agents have been shown to
reduce blood loss in patients with both normal and exaggerated
fibrinolytic responses to surgery, without apparently increasing the
risk of post-operative complications.
Description of the intervention
Antifibrinolytic agents are widely used in major surgery to prevent
fibrinolysis and reduce surgical blood loss. A recent systematic re-
view (Henry 2011) of randomised controlled trials of antifibri-
nolytics (mainly aprotinin or tranexamic acid [TXA]) in elective
surgical patients showed that antifibrinolytics reduced the num-
bers needing transfusion by one third, reduced the volume needed
per transfusion by one unit, and halved the need for further surgery
to control bleeding. These differences were all statistically signif-
icant at the P<0.01 level. Specifically, aprotinin reduced the rate
of blood transfusion by 34% (relative risk [RR]=0.66; 95% con-
fidence interval [CI] 0.60 to 0.72) and TXA by 39% (RR=0.61;
95%CI 0.53 to 0.70). Aprotinin use saved 1.02 units of red blood
cells (RBCs) (95%CI 0.79 to 1.26) in those requiring transfusion,
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and TXA use saved 0.87 units (95% CI 0.53 to 1.20). There was a
non-significant reduction in mortality with both aprotinin (RR=
0.81; 95% CI 0.63 to 1.06) and TXA (RR=0.60; 95% CI 0.33 to
1.10).
How the intervention might work
Because the coagulation abnormalities that occur after injury
are similar to those after surgery, it is possible that antifibri-
nolytic agentsmight also reduce blood loss andmortality following
trauma. A simple and widely practicable intervention that reduced
blood loss following trauma might prevent tens of thousands of
premature deaths. A reduction in the need for transfusion would
also have important public health implications. Blood is a scarce
and expensive resource and major concerns remain about the risk
of transfusion-transmitted infection. Trauma is particularly com-
mon in parts of the world where the safety of blood transfusion
cannot be assured. A recent study in Uganda estimated the popu-
lation-attributable fraction of HIV acquisition as a result of blood
transfusion to be around two percent (Kiwanuka 2004) although
some estimates are much higher (Heymann 1992).
O B J E C T I V E S
To quantify the effect of antifibrinolytic drugs on mortality, vas-
cular occlusive events, surgical intervention and receipt of blood
transfusion after acute traumatic injury.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCT), as per the following defini-
tion.
RCT: A study involving at least one intervention and one con-
trol treatment, concurrent enrolment and follow-up of the inter-
vention and control groups, and in which the interventions to be
tested are selected by a random process, such as the use of a ran-
dom numbers table (coin flips are also acceptable). If the study
author(s) state explicitly (usually by using some variant of the term
’random’ to describe the allocation procedure used) that the groups
compared in the trial were established by random allocation, then
the trial is classified as an ’RCT’.
Types of participants
People of any age following acute traumatic injury.
Types of interventions
The interventions considered are the antifibrinolytic agents: apro-
tinin, tranexamic acid (TXA) and epsilon-aminocaproic acid
(EACA).
Types of outcome measures
Primary outcomes
• Mortality at the end of the follow up.
Secondary outcomes
• Number of patients experiencing an adverse event,
specifically vascular occlusive events (myocardial infarction,
stroke, deep vein thrombosis or pulmonary embolism).
• Number of patients undergoing surgical intervention.
• Number of patients receiving blood transfusion.
• Volume of blood transfused (units).
Search methods for identification of studies
Searcheswere not restricted by date, language or publication status.
Electronic searches
We searched the following electronic databases:
• Cochrane Injuries Group’s Specialised Register (searched
July 2010)
• Cochrane Central Register of Controlled Trials Issue 3,
2010 (The Cochrane Library)
• MEDLINE (1966 to July week 2, 2010)
• PubMed (searched March 17, 2004)
• EMBASE (1980 to week 28, July 2010)
• Science Citation Index (searched March 17, 2004)
• National Research Register (issue 1, 2004)
• Zetoc (searched March 17, 2004)
• SIGLE (searched March 17, 2004)
• Global Health (searched March 17, 2004)
• LILACS (searched March 17, 2004)
• Current Controlled Trials (searched March 17, 2004)
The search strategies used in the latest update are listed in full in
Appendix 1.
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Searching other resources
All references in the identified trials and background papers were
checked and study authors contacted to identify relevant published
and unpublished data. Pharmaceutical companies were contacted
in 2004 to obtain information on ongoing trials.
Data collection and analysis
Selection of studies
The titles and abstracts identified in the electronic searches were
screened by two independent authors to identify studies that had
the potential to meet the inclusion criteria. The full reports of all
such studies were obtained. From the results of the screened elec-
tronic searches, bibliographic searches and contacts with experts,
two authors independently selected trials meeting the inclusion
criteria. There were no disagreements on study inclusion.
Data extraction and management
Two authors independently extracted information on the follow-
ing: number of randomised participants, types of participants
and types of interventions. The outcome data sought were: num-
bers of deaths in each group, numbers with vascular occlusive
events, numbers requiring surgical intervention, and the amount
of blood transfused. Information on loss to follow-up, blinding,
and whether an intention-to-treat analysis was performed was also
extracted. The authors were not blinded to the authors or journal
when doing this. Results were compared and differences would
have been resolved by discussion had there been any. Where there
was insufficient information in the published report, we attempted
to contact the authors for clarification.
Assessment of risk of bias in included studies
Two authors assessed the risk of bias for allocation concealment.
Each trial was assessed as being at high, low or unclear risk of bias
according to the criteria presented in Higgins 2008.
Assessment of heterogeneity
The presence of heterogeneity of the observed treatment effects
were assessed using the I2 statistic, which describes the percent-
age of total variation across studies due to heterogeneity rather
than chance. A value of 0% indicates no observed heterogeneity,
and larger values show increasing heterogeneity; substantial het-
erogeneity is considered to exist when I2 >50% (Higgins 2008).
The following were specified a-priori as factors that could explain
any observed heterogeneity: adequacy of allocation concealment;
injury severity based on the injury severity score (an ISS of greater
than or equal to 16 defines the severely injured strata); and ac-
cording to whether the study population included predominantly
blunt or penetrating trauma.
Assessment of reporting biases
We planned to investigate the presence of reporting (publication)
bias using funnel plots, however there were too few included stud-
ies to enable meaningful analysis.
Data synthesis
Risk ratios (RR) and 95% confidence intervals (95% CI) were
calculated. The risk ratio was chosen because it is more readily
applied to the clinical situation. For transfusion volumes, themean
difference (MD) in the units of blood transfused were calculated
with 95% CI.
Subgroup analysis and investigation of heterogeneity
We planned to conduct subgroup analyses to explore whether ef-
fect sizes vary according to the type of antifibrinolytic agent and
the dosing regimen. However there were too few trials for such
analyses.
R E S U L T S
Description of studies
Searches conducted in April 2004 identified a total of 819 records.
These were screened by two authors and the full texts of nine
potentially eligible reports were obtained for closer examination.
Of the nine potentially eligible reports, two trialsmet the inclusion
criteria. Two further trials were identified in an updated search
conducted in July 2010. In summary, four randomised controlled
trials including 20,548 randomised patients have been identified
as meeting the inclusion criteria and are included in this review.
Tranexamic acid
Two trials compared TXA with placebo in trauma patients. The
CRASH-2 2010 recruited 20,211 trauma patients with, or at risk
of, significant haemorrhage. A trial in Thailand (Yutthakasemsunt
2010) recruited 240 trauma patients with moderate to severe
traumatic brain injury. As of November 2012, the Thai trial
Yutthakasemsunt 2010 was only available as an abstract with pub-
lication of the full trial report pending. The trial has been included
based on the data reported in the abstract. The full trial data will
be incorporated into this systematic review once the full trial re-
port is available.
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Aprotinin
Two trials compared the effects of aprotininwith placebo in trauma
patients. One trial (Auer 1979) involved 20 patients with severe
head injury, and one (McMichan 1982) involved 77 patients with
a combination of hypovolaemic shock andmajor fractures of either
the lower limb, pelvis or both.
See ’Characteristics of included studies’ for further details.
Risk of bias in included studies
The CRASH-2 2010 trial was judged to be at low risk of bias.
It was a large randomised controlled trial involving 20,211 adult
trauma patients who were randomly allocated to receive TXA or
placebo. TXA and placebo were packaged in identical ampoules.
Hospitals with reliable telephone access used a telephone randomi-
sation service, hospitals without used a local pack system; alloca-
tion concealment was adequate. Participants and trial staff were
blinded to treatment allocation. Over 99% of patients were fol-
lowed up.
There was insufficient information presented in the abstract to
assess the risk of bias of the trial by Yutthakasemsunt 2010.
The trial by Auer 1979 was described as double blind. The ade-
quacy of allocation concealment was unclear. However, after ran-
domly allocating the first 20 patients, five patients were added to
the aprotinin group. Because it was not possible to separate the
outcome data for the 20 randomised and the five non-randomised
patients, this study provided no useable outcome data.
In the randomised controlled trial by McMichan 1982 the apro-
tinin and placebo were prepared in “similar ampoules”. All am-
poules were in boxes of 50, with a code number assigned to each
box. The nature of the content of the ampoules was not known to
any of the investigators nor to the attending physicians. The codes
were not broken until the end of the study. There were seven post-
randomisation exclusions from the study in which there were three
deaths. These three deaths were excluded because they occurred
within the first 24 hours (it is not clear whether or not this was
specified in the study protocol). Three patients refused the trial
investigations, and one patient was transferred to another hospital
for specialist treatment of quadriplegia and later died.
Effects of interventions
Tranexamic acid versus placebo
Mortality
Both the CRASH-2 2010 trial and the trial by Yutthakasemsunt
2010 reported mortality data.
All-cause mortality was significantly reduced with tranexamic acid
(pooled risk ratio (RR) 0.90, 95% CI 0.85 to 0.97; P=0.003:
Analysis 1.1). There was no evidence of statistical heterogeneity
(Chi²=0.77, df=1 (P=0.38); I²=0%).
The CRASH-2 2010 also presented mortality data by cause. The
risk of death due to bleeding and myocardial infarction were sig-
nificantly reduced with TXA. There were no statistically signifi-
cant differences in the risk of death from other causes:
• Bleeding: RR 0.85, 95% CI 0.76 to 0.96; P=0.0077
• Myocardial infarction: RR 0.32, 95% CI 0.14 to 0.75; P=
0.0053
• Vascular occlusion: RR 0.69, 95% CI 0.44 to 1.07; P=0.096
• Stroke: RR 1.60, 95% CI 0.52 to 4.89; P=0.40
• Pulmonary embolism: RR 0.86, 95% CI 0.46 to 1.61; P=
0.63
• Multi-organ failure: RR 0.90, 95% CI 0.75 to 1.08; P=0.25
• Head injury: RR 0.97, 95% CI 0.87 to 1.08; P=0.60
• ’Other’ causes: RR 0.94, 95% CI 0.74 to 1.20; P=0.63
Although not prespecified subgroup analyses of this review, the
effects of TXA on death due to bleeding by time to treatment,
severity of haemorrhage, Glasgow coma score, and type of injury
were assessed in the CRASH-2 trial (CRASH-2 2011). The results
are presented below.
Analysis of the risk of death due to bleeding indicated that the effect
of TXA varied by time to treatment. Treatment within one hour
of injury was associated with a 32% relative reduction in risk of
death due to bleeding (RR 0.68, 95% CI 0.57 to 0.82; P<0.0001)
and treatment between 1 and 3 hours after injury was associated
with a 21% reduction (RR 0.79, 95% CI 0.64 to 0.97; P=0.03).
TreatmentwithTXAafter three hours of injurywas associatedwith
a 44% relative increase in risk of death due to bleeding (RR 1.44,
95% CI 1.12 to 1.84; P=0.004). Test for subgroup differences:
Chi²=23.51, P<0.00001.
There was no evidence that the effect of TXA on death due to
bleeding varied by the severity of haemorrhage, Glasgow coma
score, or type of injury:
• Severity of haemorrhage (as assessed by systolic blood
pressure): >89 mm Hg (RR 0.88, 95% CI 0.71 to 1.10); 76-89
(RR 1.01, 95% CI 0.79 to 1.30); ≤75 (RR 0.81, 95% CI 0.69
to 0.95). Test for subgroup differences: Chi²=2.24, P=0.33.
• Glasgow coma score: severe (RR 0.92, 95% CI 0.76 to
1.13); moderate (RR 0.77, 95% CI 0.59 to 0.99); mild (RR
0.86, 95% CI 0.72 to 1.02). Test for subgroup differences:
Chi²=1.28, P=0.53.
• Type of injury: blunt (RR 0.89, 95% CI 0.77 to 1.04);
penetrating (RR 0.79, 95% CI 0.66 to 0.96). Test for subgroup
differences: Chi²=0.92, P=0.34.
Vascular occlusive events
The CRASH-2 2010 trial reported data on vascular occlusive
events. There was no difference in the risk of experiencing one
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or more vascular occlusive events (fatal or non-fatal; myocardial
infarction, stroke, pulmonary embolism, deep vein thrombosis)
between the TXA and placebo groups (RR 0.84, 95% CI 0.68 to
1.02; P=0·084). TXA reduced the risk of myocardial infarction
(RR 0.64, 95% CI 0.42 to 0.97; P=0.035). There was no differ-
ence in the risk of stroke (RR 0.86, 95%CI 0.61 to 1.23; P=0.42),
pulmonary embolism (RR 1.01, 95% CI 0.73 to 1.41; P=0.93) or
deep vein thrombosis (RR 0.98, 95% CI 0.63 to 1.51; P=0.91).
Surgical intervention
Data from the CRASH-2 2010 trial suggest that there is no sta-
tistically significant difference in the risk of receiving one or more
surgical interventions (neurosurgery, chest, abdominal or pelvic
surgery) (RR 1.00, 95% CI 0.97 to 1.03; P=0.79) Analysis 1.2.
Receipt of blood transfusion
Of the patients allocated to TXA in the CRASH-2 2010 trial,
5067 (50.4%) received a blood product transfusion versus 5160
(51.3%) of the patients allocated to placebo (RR 0.98, 95% CI
0.96 to 1.01; P=0.21) Analysis 1.3. There was no difference in the
average number of blood units transfused (MD -0.17; 95% CI -
0.39 to 0.05; P=0.13) Analysis 1.4.
Aprotinin versus placebo
The study by Auer 1979, with 20 randomised patients, provided
no useable outcome data for the reasons outlined above. The study
by McMichan 1982, with 77 randomised patients (seven post-
randomisation exclusions), was reported in four separate reports
(Rosengarten 1977; Rosengarten 1979 and McMichan 1977 in
’included studies’ reference McMichan 1982).
Mortality
McMichan 1982 reported mortality data; there was no difference
in the risk of death between the aprotinin or placebo groups (RR
0.14, 95% CI 0.01 to 2.67; P=0.19) Analysis 2.1.
Vascular occlusive events
Data on vascular occlusive events were not reported.
Surgical intervention
McMichan 1982 reported data on the number of patients under-
going a surgical intervention; there was no difference between the
aprotinin or placebo groups (RR 1.07, 95% CI 0.87 to 1.33; P=
0.53) Analysis 2.2.
Receipt of blood transfusion
Data on the number of patients receiving a blood transfusion were
not reported. The volume of blood transfused was reported, there
was no difference between groups (MD -0.40 units; 95% CI -
0.91, 0.11; P=0.12) Analysis 2.3.
D I S C U S S I O N
Summary of main results
Tranexamic acid reduces all-cause mortality in bleeding trauma
patients, with no apparent increase in the risk of vascular occlusive
events. This conclusion is based on the results of the CRASH-2
2010 trial which recruited 20,211 bleeding trauma patients from
274 hospitals in 40 countries.
Overall completeness and applicability of
evidence
The large numbers of patients in a wide range of different health
care settings around the world studied in the CRASH-2 2010 trial
help the result to be widely generalised. The treatment is effective
in patients with blunt and penetrating trauma. Because TXA is
inexpensive and easy to administer, it could readily be added to
the normal medical and surgical management of bleeding trauma
patients in hospitals around the world.
Each year, worldwide, about four million people die as a result
of traumatic injuries and violence. Approximately 1.6 million
of these deaths occur in hospital and about one third of these
deaths (480,000) are from haemorrhage. The CRASH-2 2010
trial has shown that TXA reduces mortality from haemorrhage by
about one sixth. If this widely practicable intervention was used
worldwide in the treatment of bleeding trauma patients, it could
prevent over 70,000 deaths each year (see Table 1).
Many trauma patients suffer a brain injury. Traumatic brain in-
jury (TBI) is commonly accompanied by intracranial bleeding
which can develop or worsen after hospital admission. Traumatic
intracranial haemorrhage is associated with an increased risk of
death and disability, and regardless of location, haemorrhage size
is strongly correlated with outcome. If TXA reduced intracranial
bleeding after isolated TBI then this could improve patient out-
comes. Although, many of the bleeding trauma patients included
in the CRASH-2 2010 trial also suffered a brain injury, it is possi-
ble that the effects of TXAmay differ in patients with isolatedTBI.
The trial by Yutthakasemsunt 2010 provides some promising evi-
dence for the beneficial effect of TXA onmortality in patients with
isolated TBI; however, further evidence is required from larger tri-
als which also assess the effect on disability.
There is no evidence for the effect of aprotinin for trauma.
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Quality of the evidence
The quality of the evidence supporting the use of tranexamic acid
for trauma is high. The findings of this review are based primarily
on the results of the CRASH-2 2010 trial. This was a large, high
quality randomised trial with low risk of bias. Sequence generation
was appropriately randomised, allocation was concealed and par-
ticipants, trial personnel and outcome assessors were all blinded.
Furthermore, there were minimal missing data with over 99% of
patients followed up.
Potential biases in the review process
This systematic review addresses a focused research question and
uses pre-defined inclusion criteria and methodology to select and
appraise eligible trials.
As with all systematic reviews, the possibility of publication bias
should be considered as a potential threat to validity. However, in
light of our extensive and sensitive searching we believe that the
risk of such a bias affecting the results is minimal.
Agreements and disagreements with other
studies or reviews
A systematic review of randomised trials assessing the effects of
TXA in patients undergoing elective surgery has been conducted
(Henry 2011). This review found that compared to control, TXA
reduced the need for blood transfusion without any apparent in-
crease in the risk of adverse events. Unlike the Henry 2011 review,
we found no evidence of any substantial reduction in the receipt of
a blood transfusion or the amount of blood transfused in trauma
patients. One possible explanation is that in the CRASH-2 2010
trial, following the loading dose, TXA was infused over a period
of eight hours, whereas decisions about transfusion are made very
soon after hospital admission. The absence of any large effect on
blood transfusion may also reflect the difficulty of accurately esti-
mating blood loss in trauma patients when assessing the need for
transfusion. Finally, the absence of any substantial reduction in
transfusion requirements in patients treated with TXA acid may
reflect the fact that there were fewer deaths in patients allocated
to TXA acid than to placebo and patients who survive as a result
of TXA administration would have had a greater opportunity to
receive a blood transfusion (competing risks).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Tranexamic acid (TXA) safely reduces mortality in bleeding
trauma patients. As there is evidence that the effect on death due
to bleeding depends on the time interval between the injury and
treatment, TXA should be given as early as possible and within
three hours of the injury as treatment later than this is unlikely to
be effective.
Implications for research
The knowledge that TXA safely reduces the risk of death from
traumatic bleeding raises the possibility that it might also be effec-
tive in other situations where bleeding can be life threatening or
disabling and further research is warranted to explore this poten-
tial. Randomised trials involving patients with isolated traumatic
brain injury that assess both mortality and disability outcomes are
required before TXA can be recommended for use in these pa-
tients. The ongoing CRASH-3 trial with a planned sample size
of 10,000 patients with traumatic brain injury, will contribute to
resolving the uncertainty about the effects of TXA in this group.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Auer 1979
Methods Probable RCT: “Twenty patients were included in a double-blind study; nine patients
were treated with Trasylol. Eleven received a placebo drug.” Five additional (non-randomly
allocated) patients were added to the study and received aprotinin treatment. These patients
were not separated out in the analysis
Participants Patients with severe head injury who had remained comatose for seven days. Most of them
had clinical brain stem signs
Interventions Aprotinin group: 500,000 IE initially thereafter 200,000 IV every four hours
Outcomes Death.
Range of biochemical end points.
Notes Because it was not possible to separate the 5 non-randomised patients from the 20 probably
randomised patients, this study provides no useable outcome data
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Unclear.
CRASH-2 2010
Methods RCT: Randomisation was balanced by centre, with an allocation sequence based on a block
size of eight, generated with a computer random number generator. Participants and study
staff were blind to treatment allocation
Participants 20,211 adult (>16 years) trauma patients with, or at risk of, significant bleeding
Interventions Tranexamic acid group: loading dose 1g over 10 minutes then infusion of 1g over 8 hours
Matching placebo.
Outcomes Death.
Vascular occlusive events.
Blood transfusion requirements.
Disability.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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CRASH-2 2010 (Continued)
Allocation concealment (selection bias) Low risk TXA and placebo were packaged in identi-
cal ampoules. Hospitals with a reliable tele-
phone access used a telephone randomisa-
tion service, hospitals without used a local
pack system
McMichan 1982
Methods RCT: Aprotinin and placebo were supplied in identical coded ampoules. Ampoules were in
boxes of 50 with a code number assigned to each box. These numbers were randomised in
groups of 20 and each batch was assigned in numerical order. The codes were not broken
until the end of the study
Patients excluded after randomisation were those who died within the first 24 hours or
refused continuing investigation
Participants Patients with a combination of hypovolaemic shock and major fractures of the lower limb
and or pelvis. Patients seen 12 or more hours after injury and those with major head or
chest injuries were excluded
Interventions Aprotinin group: 500,000 Kallikrein Inhibitor Units (KIU) IV statim followed by 300,000
KIU at 6-hour intervals for 96 hours
Outcomes Death.
Mean blood transfusion.
Respiratory function.
Notes 77 patients were randomised but there were 7 post-randomisation exclusions. Among the
7 excluded patients, there were 3 deaths within the first 24 hours of injury. One patient was
transferred to another hospital because of quadriplegia and died later, and three patients
refused investigation.
It was noted in the results that the data on transfusion requirement was found to have a
non-normal distrubution. Nevertheless, the mean and standard deviation were presented
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Aprotinin and placebo were prepared in
“similar ampoules”. All ampoules were in
boxes of 50, with a code number assigned to
each box. The nature of the content of the
ampoules was not known to any of the in-
vestigators nor to the attending physicians.
The codes were not broken until the end of
the study
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Yutthakasemsunt 2010
Methods RCT
Participants 240 adults patients (>16 years) with moderate to severe traumatic brain injury (Glasgow
Coma Scale 4 to 12) within 8 hours of injury
Interventions Tranexamic acid group: 2g.
Matching placebo.
Outcomes Death.
Progressive intracranial haemorrhage.
Disability (GOS).
Thromboembolic events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gierhake 1971 Types of patients: general surgery patients not trauma.
Husted 2003 Types of patients: orthopaedic patients not trauma.
Klobow 1977a Types of interventions: trasylol compared with heparin.
Klobow 1977b Types of interventions: trasylol compared with heparin.
Kuiian 1999 Types of studies: After Dr Vasiliy Vlassov, Director of the Russian Branch of the Nordic Cochrane Centre kindly
translated the methods section it was clear that this study was not randomised
Loew 1970 Types of studies: alternation used not random allocation.
Nissen 1989 Types of studies: review article not randomised controlled trial
Schneider 1976 Types of studies: randomisation in this trial was by allocating patients to the treatment group according to the day
of admission. However, this procedure was subverted for large numbers (813) of patients in which case the study
cannot be considered to be a randomised controlled trial
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Characteristics of ongoing studies [ordered by study ID]
CRASH-3
Trial name or title Clinical Randomisation of an Antifibrinolytic in Significant Head Injury (CRASH-3)
Methods Large, international, randomised, placebo controlled trial.
Participants Adults with traumatic brain injury, who are within eight hours of injury, with any intracranial bleeding on
CT scan or who have a GCS of 12 or less, and have no significant extra-cranial haemorrhage, are eligible for
inclusion, except those for whom antifibrinolytic agents are thought to be clearly indicated or clearly contra-
indicated
Interventions Loading dose of tranexamic acid (1 gram by intravenous injection) or placebo (sodium chloride 0.9%) given
as soon as possible after
randomisation. Maintenance dose of tranexamic acid (1 gram by intravenous injection) or placebo (sodium
chloride 0.9%) given after the loading dose is finished
Outcomes Primary outcome is death inhospital within 28days of injury. Secondary outcomes are vascular occlusive events
(myocardial infarction, pulmonary embolism, clinical evidence of deep vein thrombosis), stroke, disability,
seizures, neurosurgical intervention, days in intensive care, other adverse events
Starting date July 2012
Contact information crash@Lshtm.ac.uk
Notes Current Controlled Trials ISRCTN15088122; Clinicaltrials.gov NCT01402882
The JP Moulton Charitable Trust, UK, is funding the run-in costs for the trial and up to 500 patients’
recruitment. Full funding is being sought from public funding organisations for the main trial
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D A T A A N D A N A L Y S E S
Comparison 1. Tranexamic acid versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 2 20367 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.85, 0.97]
2 Proportion undergoing surgical
intervention
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Proportion receiving blood
transfusion
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4 Volume of blood transfused 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Comparison 2. Aprotinin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Proportion undergoing surgical
intervention
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Volume of blood transfused 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Tranexamic acid versus placebo, Outcome 1 All-cause mortality.
Review: Antifibrinolytic drugs for acute traumatic injury
Comparison: 1 Tranexamic acid versus placebo
Outcome: 1 All-cause mortality
Study or subgroup TXA Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRASH-2 2010 1463/10060 1613/10067 98.9 % 0.91 [ 0.85, 0.97 ]
Yutthakasemsunt 2010 12/120 18/120 1.1 % 0.67 [ 0.34, 1.32 ]
Total (95% CI) 10180 10187 100.0 % 0.90 [ 0.85, 0.97 ]
Total events: 1475 (TXA), 1631 (Placebo)
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours TXA Favours placebo
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Analysis 1.2. Comparison 1 Tranexamic acid versus placebo, Outcome 2 Proportion undergoing surgical
intervention.
Review: Antifibrinolytic drugs for acute traumatic injury
Comparison: 1 Tranexamic acid versus placebo
Outcome: 2 Proportion undergoing surgical intervention
Study or subgroup TXA Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRASH-2 2010 4814/10060 4836/10067 1.00 [ 0.97, 1.03 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 4814 (TXA), 4836 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours TXA Favours placebo
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Analysis 1.3. Comparison 1 Tranexamic acid versus placebo, Outcome 3 Proportion receiving blood
transfusion.
Review: Antifibrinolytic drugs for acute traumatic injury
Comparison: 1 Tranexamic acid versus placebo
Outcome: 3 Proportion receiving blood transfusion
Study or subgroup TXA Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
CRASH-2 2010 5067/10060 5160/10067 0.98 [ 0.96, 1.01 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5067 (TXA), 5160 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours TXA Favours placebo
Analysis 1.4. Comparison 1 Tranexamic acid versus placebo, Outcome 4 Volume of blood transfused.
Review: Antifibrinolytic drugs for acute traumatic injury
Comparison: 1 Tranexamic acid versus placebo
Outcome: 4 Volume of blood transfused
Study or subgroup Tranexamic acid Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
CRASH-2 2010 10060 3.05 (7.7) 10067 3.22 (8.02) -0.17 [ -0.39, 0.05 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours TXA Favours placebo
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Analysis 2.1. Comparison 2 Aprotinin versus placebo, Outcome 1 Death.
Review: Antifibrinolytic drugs for acute traumatic injury
Comparison: 2 Aprotinin versus placebo
Outcome: 1 Death
Study or subgroup Aprotinin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McMichan 1982 0/35 3/35 0.14 [ 0.01, 2.67 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Aprotinin), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours aprotinin Favours placebo
Analysis 2.2. Comparison 2 Aprotinin versus placebo, Outcome 2 Proportion undergoing surgical
intervention.
Review: Antifibrinolytic drugs for acute traumatic injury
Comparison: 2 Aprotinin versus placebo
Outcome: 2 Proportion undergoing surgical intervention
Study or subgroup Aprotinin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
McMichan 1982 30/35 28/35 1.07 [ 0.87, 1.33 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 30 (Aprotinin), 28 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.5 0.7 1 1.5 2
Favours aprotinin Favours placebo
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Analysis 2.3. Comparison 2 Aprotinin versus placebo, Outcome 3 Volume of blood transfused.
Review: Antifibrinolytic drugs for acute traumatic injury
Comparison: 2 Aprotinin versus placebo
Outcome: 3 Volume of blood transfused
Study or subgroup Aprotinin Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
McMichan 1982 35 1.2 (0.8) 35 1.6 (1.3) -0.40 [ -0.91, 0.11 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours aprotinin Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Deaths that could be avoided by the administration of TXA to bleeding trauma patients (ten countries with the
highest numbers of avoided deaths shown)
Country Trauma deaths Haemorrhage deaths Deaths averted with TXA
India 714,730 85,768 12,865
China 667,277 80,073 12011
Indonesia 279,499 33,534 5030
Russia 246,836 29,620 4443
Brazil 122,953 14,754 2206
USA 122,529 14,703 2206
Iraq 99,968 11,996 1799
Nigeria 87,811 10,537 1581
Bangladesh 76,938 9233 1385
DRC 73,579 8829 1324
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Table 1. Deaths that could be avoided by the administration of TXA to bleeding trauma patients (ten countries with the
highest numbers of avoided deaths shown) (Continued)
World 4,100,645 492,077 73,812
Trauma and haemorrhage death estimates taken from the WHO Global Burden of Disease Study: http://www.who.int/healthinfo/
global˙burden˙disease/en/
A P P E N D I C E S
Appendix 1. Search strategy
Cochrane Injuries Group Specialised Register (searched July 2010)
(Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor* or
basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren
or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal
or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?
128 or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal
type trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) or
riker?52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren) or (tranexamic or Cyclo-
hexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi
2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclohexane carboxy-
late or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron
or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane carbonic acid
or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or
aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336 or cyclo-
capron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA) or (aminocaproic or
amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116
or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or amino n hexanoic or
acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol or cl 10304 or EACA
or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or epsilon aminocaproate
or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?177or neocaprol or nsc?
26154 or tachostyptan)
Cochrane Central Register of Controlled Trials 2010, Issue 3 (The Cochrane Library)
#1 MeSH descriptor Antifibrinolytic Agents explode all trees
#2 (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* ):ab,ti or ((plasmin
or fibrinolysis) near3 inhibitor*):ab,ti
#3 MeSH descriptor Aprotinin explode all trees
#4 (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor*
or basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren
or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal
or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?
128 or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal
type trypsin inhibitor or riker?52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren or
midran):ab,ti or ((Kunitz near3 inhibitor*) or (pancrea* near3 antitrypsin) or (pancrea* near3 trypsin next inhibitor*)):ab,ti
#5 MeSH descriptor Tranexamic Acid explode all trees
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#6 (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-
amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclo-
hexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin
or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane
carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecar-
boxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336
or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA):ab,ti
#7 MeSH descriptor Aminocaproic Acids explode all trees
#8 MeSH descriptor 6-Aminocaproic Acid explode all trees
#9 (epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic
or amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol
or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or
epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?
177or neocaprol or nsc?26154 or tachostyptan):ab,ti
#10 (aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic):ab,ti
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
MEDLINE(Ovid) 1950 to July Week 2 2010
1.exp Antifibrinolytic Agents/
2.(anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or ((plasmin or
fibrinolysis) adj3 inhibitor*)).ab,ti.
3.exp Aprotinin/
4.(Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor*
or basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren
or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal or
pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?128
or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type
trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) or riker?
52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren).ab,ti.
5.exp Tranexamic Acid/
6.(tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-
amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclo-
hexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin
or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane
carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecar-
boxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336
or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti.
7.exp Aminocaproic Acids/ or exp 6-Aminocaproic Acid/
8.(((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic) adj2 acid*) or
epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or
amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol
or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or
epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?
177or neocaprol or nsc?26154 or tachostyptan).ab,ti.
9.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10.randomi?ed.ab,ti.
11.randomized controlled trial.pt.
12.controlled clinical trial.pt.
13.placebo.ab.
14.clinical trials as topic.sh.
15.randomly.ab.
16.trial.ti.
17.10 or 11 or 12 or 13 or 14 or 15 or 16
18.(animals not (humans and animals)).sh.
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19.17 not 18
20.9 and 19
EMBASE (Ovid) 1980 to 2010 (Week 28)
1.exp Antifibrinolytic Agent/
2.(anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or ((plasmin or
fibrinolysis) adj3 inhibitor*)).ab,ti.
3.exp Aprotinin/
4.(Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor*
or basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren
or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal or
pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?128
or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type
trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) or riker?
52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren).ab,ti.
5.exp Tranexamic Acid/
6.(tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-
amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclo-
hexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin
or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane
carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecar-
boxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336
or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti.
7.exp Aminocaproic Acid/
8.(((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic) adj2 acid*) or
epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or
amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol
or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or
epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?
177or neocaprol or nsc?26154 or tachostyptan).ab,ti.
9.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10.exp Randomized Controlled Trial/
11.exp controlled clinical trial/
12.randomi?ed.ab,ti.
13.placebo.ab.
14.*Clinical Trial/
15.randomly.ab.
16.trial.ti.
17.10 or 11 or 12 or 13 or 14 or 15 or 16
18.exp animal/ not (exp human/ and exp animal/)
19.17 not 18
20.9 and 19
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WH A T ’ S N E W
Last assessed as up-to-date: 14 July 2010.
Date Event Description
5 November 2012 New search has been performed Additional data from the CRASH-2 trial of the effects of tranexamic acid on
death due to bleeding according to time to treatment, severity of haemor-
rhage, Glasgow coma scale and type of injury, have been incorporated
The conclusions have been edited to emphasise the importance of early ad-
ministration (≤3 hours of injury) of tranexamic acid
H I S T O R Y
Protocol first published: Issue 3, 2004
Review first published: Issue 4, 2004
Date Event Description
22 November 2010 New citation required and conclusions have changed Two new trials (CRASH-2 2010 - 20,211 bleeding
trauma patients) and Yutthakasemsunt 2010 2010 -
240 patients with traumatic brain injury) have been
included
The objectives of the review have been amended. The
Results, Discussion and Conclusions sections have
been amended accordingly
C O N T R I B U T I O N S O F A U T H O R S
TC helped design the protocol, identified the included trials, extracted data and drafted the final version of the review.
IR helped design the protocol, identified the included trials, extracted data and drafted the final version of the review.
HS helped design the protocol and draft the final version of the review.
KK helped identify the included trials, extract data and revised the text of the review for the November 2010 and 2012 updates.
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D E C L A R A T I O N S O F I N T E R E S T
Tim Coats, Haleema Shakur and Ian Roberts were investigators in the CRASH-2 trial.
Haleema Shakur and Ian Roberts are investigators in the ongoing CRASH-3 trial.
Ian Roberts: LSHTM has received funds from pharmaceutical companies to pay for the drug and placebo used in RCTs of tranexamic
acid in acute severe bleeding. These funds are delared in the relevant publications.
Haleema Shakur: I am an investigator and grant holder for the WOMAN Trial of tranexamic acid for the treatment of postpartum
hemorrhage, the CRASH-3 trial of tranexamic acid for the treatment of traumatic brain injury and the Halt-it trial of tranexamic acid
for the treatment of gastrointestinal bleeding.
Katharine Ker: none known.
S O U R C E S O F S U P P O R T
Internal sources
• London School of Hygiene & Tropical Medicine, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The objectives of the reviewhave changed. Reducing blood loss has been removed, and vascular occlusive events and surgical intervention
have been added as outcomes.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Aminocaproic Acid [therapeutic use]; Antifibrinolytic Agents [∗therapeutic use]; Aprotinin [therapeutic use]; Blood Loss, Surgical
[prevention & control]; Blood Transfusion [∗utilization]; Hemorrhage [∗drug therapy; etiology; mortality]; Randomized Controlled
Trials as Topic; Tranexamic Acid [therapeutic use]; Wounds and Injuries [∗complications; mortality]
MeSH check words
Humans
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